Among these PPARγ agonists, pioglitazone is commonly used for the treatment of T2DM and exhibits anticancer properties, including inhibiting cancer cell proliferation, invasion, migration, and resistance to apoptosis, which are mediated by downregulating certain genes that interfere with carcinogenic cell pathways [11,21,26,27]. This evidence concerns the gene PPARG and cancer.